Recent advances in systemic therapies have led to the development of PD-1 checkpoint inhibitors, which one expert says may represent a paradigm shift in the treatment and management of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (SCC).
Ilya Petrou. M.D.
It is important for clinicians to stay abreast with the latest data coming out of trials and individually consult their hair loss patients accordingly on a case by case basis, says this expert.
Continued research has produced a number of targeted therapies that provide hope for patients with this rare but sometimes deadly form of nonmelanoma skin cancer.
Positive outcomes with an experimental vaccine provide hope for patients with stage IIB and IIC melanoma.
Though still considered controversial, several evolving treatment and management plans for primary cutaneous melanoma are making their way into the mainstream and challenging more traditional approaches.
New joint AAD-NPF guidelines consider the quality-of-life impact of pediatric psoriasis as well as comorbidity risks in this patient population.
Gene expression profile (GEP) testing outcomes have positively impacted the management decision-making process for cutaneous squamous cell carcinoma (cSCC), according to a recent study.
A novel cocktail of topically applied botanicals has recently proven useful in the treatment and management of mild-to-moderate atopic dermatitis in children, offering hope for this patient population.
Newer treatment approaches may soon become mainstream in the treatment and management of keloids, one expert says.
Fruits and vegetables rich in vitamin A appear to play a significant role in helping to decrease the incidental risk of developing squamous cell carcinoma, according to a recent study.